VRTX

Vertex Pharmaceuticals is a biotechnology company developing medicines across multiple therapeutic areas including cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, with approved products already on the market in these areas. The pipeline includes mid- and late-stage clinical programs using various modalities to address kidney diseases (IgA nephropathy, APOL1-mediated disease, primary membranous nephropathy, and autosomal dominant polycystic kidney disease), neuropathic pain, type 1 diabetes, and myotonic dystrophy type 1. Five pivotal programs are currently advancing through clinical development, including povetacicept for IgA nephropathy, which has completed enrollment in Phase 3 testing.

Pipeline

Catalyst Calendar